Main Uses of Streptomycin

Streptomycin is an antibiotic belonging to the aminoglycoside class. It is primarily utilized to treat several serious bacterial infections by inhibiting the ability of bacteria to synthesize essential proteins, which ultimately leads to bacterial cell death.

Treatment of Tuberculosis

The most significant application of streptomycin is in the treatment of tuberculosis (TB). It was the first antibiotic found to be effective against Mycobacterium tuberculosis. In modern medicine, it is typically used as part of a multi-drug regimen, especially in cases where the infection is resistant to first-line medications or in specific clinical presentations of the disease.

Other Bacterial Infections

Streptomycin is also indicated for the treatment of various other severe infections caused by sensitive strains of bacteria, including:

• Plague: It is considered a primary treatment for infections caused by Yersinia pestis.
• Tularemia: It is highly effective against Francisella tularensis, the causative agent of rabbit fever.
• Burusellosis: Often used in combination with other antibiotics to treat this zoonotic infection.
• Endocarditis: It may be used to treat bacterial endocarditis caused by certain species of Streptococcus or Enterococcus, usually in combination with other antimicrobial agents.

Benefits of Treatment

Targeted Antimicrobial Action

Streptomycin provides a targeted approach for treating specific gram-negative and some gram-positive bacterial infections. Its mechanism of action allows it to be effective even when other classes of antibiotics, such as penicillins, may not be suitable or effective against the specific pathogen.

Role in Combination Therapy

A major benefit of streptomycin is its role in combination therapy. By using streptomycin alongside other antibiotics, healthcare providers can improve the success rate of treatment for complex infections and help reduce the likelihood of bacteria developing resistance to any single medication.

Long-standing Efficacy

As one of the earliest discovered antibiotics, streptomycin has a well-documented history of efficacy in treating life-threatening diseases like the plague and tuberculosis. Its continued use in specific medical contexts highlights its enduring importance in the management of severe infectious diseases.

Who Can and Cannot Use Streptomycin?

The population eligibility for Streptomycin is defined by strict regulatory criteria concerning hypersensitivity, pregnancy, and organ function, as documented in official prescribing information.

---

Contraindications and Absolute Restrictions

Streptomycin is contraindicated and must not be used by two primary groups:

• Patients with a known history of hypersensitivity to Streptomycin or to other aminoglycoside antibiotics.
• Pregnant women, due to the documented, irreversible risk of fetal ototoxicity, which can cause congenital deafness.

---

Restricted and Conditional Use

Use is highly restricted and requires extreme caution in certain populations due to the drug’s potential for toxicity, particularly related to the kidneys and nerves:

• Impaired Renal Function: Patients with kidney impairment or prerenal azotemia require extreme caution, as the drug's accumulation increases the risk of severe neurotoxic and nephrotoxic reactions.
• Age Extremes: Older adults often require dosage adjustment due to age-related decline in renal function. Very young infants also require caution due to immature kidney function.
• Nerve and Muscle Conditions: Caution is necessary for patients with pre-existing VIII Cranial Nerve impairment or those with Myasthenia Gravis or Parkinson's Disease, due to risks of increased neurotoxicity or neuromuscular blockade.

---

Pregnancy Status: Contraindicated.

Lactation Status: Permitted (Monitoring for infant gastrointestinal effects is noted).

The interaction profile of Streptomycin sulfate is defined by its potential for additive organ toxicity and specific pharmacodynamic risks, as documented in official regulatory labeling.

Documented Drug-Drug Interactions

Co-administration with other ototoxic drugs (such as the chemotherapy agent Cisplatin or potent loop diuretics like Furosemide or Ethacrynic acid) is restricted because it potentiates the risk of permanent ototoxicity, leading to potential damage to the auditory or vestibular systems. Concurrent or sequential use with nephrotoxic drugs (including Vancomycin, Amphotericin B, or certain other aminoglycosides) is also limited due to the increased potential for nephrotoxicity (kidney damage).

Streptomycin may potentiate the effects of neuromuscular blocking agents (such as Rocuronium or Vecuronium) and general anesthetics, carrying a specific risk of prolonged respiratory paralysis. Furthermore, co-administration with live bacterial vaccines (e.g., typhoid vaccine) is formally contraindicated by regulatory documents due to the risk of compromising vaccine efficacy through pharmacodynamic antagonism.

High doses of certain beta-lactam antibiotics can inactivate Streptomycin in patients with severe kidney impairment, an interaction that may reduce its exposure. The severity of toxicity-related interactions is sharply increased in patients with pre-existing impaired renal function, as the drug’s clearance is dependent on the kidneys, leading to accumulation. No specific interactions requiring timing separation or prohibition with food, alcohol, or herbal products are explicitly documented in the official regulatory information for the injection form.

Streptomycin is an aminoglycoside bactericidal agent that functions by irreversibly disrupting a critical cellular process: protein synthesis. Its effect is initiated through two main mechanistic domains.

Targeting the 30S Ribosomal Subunit

The drug's action begins with the irreversible binding to the 30S subunit of the bacterial ribosome. This target interaction immediately prevents the accurate assembly of the translational machinery, leading to a permanent failure in complete protein assembly. This binding process is an energy-dependent step, which is a key mechanical constraint that limits the drug's activity against bacteria lacking the required metabolic pathway.

Induction of Translational Errors

Following binding, Streptomycin physically distorts the ribosomal decoding site, which forces the cell to commit widespread translational errors (codon misreading). This cascade results in the mass production of non-functional and toxic proteins. When these faulty structures, particularly those destined for the cell membrane, are incorporated, they lead to irreversible cellular damage and lysis, culminating in the bactericidal effect (bacterial death).

Administration Overview

Streptomycin is an aminoglycoside antibiotic administered via intramuscular injection. This route of administration is chosen to ensure the medication enters the bloodstream directly, as it is not effectively absorbed through the gastrointestinal tract. Under clinical supervision, the injection is typically rotated among different large muscle groups, such as the upper outer quadrant of the buttock or the mid-lateral thigh, to minimize local tissue irritation.

Preparation and Handling

The medication is usually supplied as a dry powder that requires reconstitution with a sterile liquid, such as sterile water for injection or physiological saline. Once the powder is completely dissolved, the resulting solution should be inspected for clarity. A clear, colorless to slightly yellow solution is standard. If the liquid contains visible particles or shows significant discoloration, it is generally not used.

Treatment Consistency

Maintaining a consistent level of the medication in the body is a primary goal of the treatment process. To achieve this, the administration follows a specific schedule determined by a healthcare provider. Completing the full course of the medication is a standard practice in antibiotic therapy to address the underlying bacterial presence effectively, even if physical symptoms appear to improve before the supply is exhausted.

Clinical Monitoring

While the medication is being used, healthcare providers often conduct regular assessments. These may include periodic laboratory tests or physical evaluations to monitor how the body is responding to the treatment. This oversight helps in managing the overall duration and progression of the therapy.

Streptomycin is an aminoglycoside antibiotic and was the first drug demonstrated to have activity against Mycobacterium tuberculosis. While its use was widespread following its discovery in 1944, the rapid emergence of resistance led to its eventual role as a second-line agent, typically administered as part of combination therapy.

Current Role in Tuberculosis (TB) Treatment

Recent clinical evidence and global guidelines, such as those from the World Health Organization (WHO), recommend limited use of streptomycin for drug-resistant TB, often in favor of newer oral agents or other injectable aminoglycosides like amikacin. Streptomycin is currently classified as a Group C agent for use in longer multidrug-resistant (MDR-TB) regimens under specific circumstances.

However, ongoing research has explored its utility in certain scenarios, particularly for patients with isolates exhibiting low-level streptomycin resistance but high-level resistance to other second-line aminoglycosides like amikacin or kanamycin. Studies have examined the significance of various genetic mutations (rpsL, rrs, and gidB) in determining resistance levels and informing treatment selection.

Comparative Efficacy

Clinical data reviews, including meta-analyses, have compared the effectiveness of different second-line injectable agents for MDR-TB. When aminoglycosides were used and drug susceptibility results supported their activity, streptomycin was associated with outcomes comparable to, or in some studies, more favorable than, those of kanamycin and capreomycin.

Safety and Monitoring

Streptomycin is associated with recognized toxicities. The primary concern across clinical studies is ototoxicity (damage to the hearing and/or balance nerves), which can be permanent. Nephrotoxicity (kidney damage) is also a known risk. Due to these risks, monitoring procedures, including regular audiometry and renal function tests, are utilized when the drug is administered, particularly in resource-limited settings where monitoring poses a significant challenge.

Common questions about Streptomycin (FAQ)

---

Q: What is the main reason Streptomycin is prescribed today, compared to other antibiotics?

Official documents state that Streptomycin is approved for several serious bacterial infections, including tuberculosis (TB), plague, and tularemia. For TB, it is often used in combination with other drugs, especially when drug-resistant strains are present. This role as a powerful agent means its use is generally reserved for severe, specific infections.

---

Q: What types of bacteria is Streptomycin specifically used to treat?

According to official prescribing information, Streptomycin is used to treat infections caused by specific susceptible organisms. This includes the bacteria responsible for conditions such as plague (Yersinia pestis) and tularemia (Francisella tularensis), in addition to its well-known role against Mycobacterium tuberculosis.

---

Q: Is Streptomycin considered a 'last resort' antibiotic?

Regulatory classification indicates that Streptomycin is a second-line agent for treating tuberculosis. Its use is typically reserved for situations where first-line medications have failed or when the infection is known to be resistant to more common antibiotics.

---

Q: What is the general expected duration of treatment with Streptomycin?

The duration of treatment depends on the specific infection being treated and the official regimen prescribed. For tuberculosis, treatment protocols often require several months, sometimes lasting 6–9 months in total. Other acute, severe infections may require a minimum of 10 days of therapy.

---

Q: Are the hearing or balance problems from Streptomycin always permanent?

Official information states that hearing loss (cochlear damage) related to the drug can be irreversible and permanent. However, balance issues (vestibular symptoms) may sometimes be reversible if the medication is stopped quickly after the symptoms first appear. Such risks are managed by the healthcare team through regular monitoring procedures.

---

Q: What are the early signs of potential hearing problems caused by Streptomycin?

The first noticeable signs of potential neurotoxicity often involve the vestibular system, which is responsible for balance. These early symptoms may include feeling dizzy, experiencing vertigo (a sensation of spinning), or feeling generally off-balance (disequilibrium).

---

Q: Can Streptomycin cause nerve damage, and what are the symptoms of this?

Yes, regulatory warnings indicate that Streptomycin is associated with neurotoxicity (damage to the nervous system). This may manifest as disturbances to the hearing and balance nerves, or, in some cases, symptoms like optic nerve dysfunction (affecting vision) or peripheral neuritis.

---

Q: What is the risk of having a severe allergic reaction to Streptomycin?

Official drug warnings state that Streptomycin may cause severe allergic reactions, including anaphylaxis. This is described by regulatory sources as a severe, acute reaction. It may be signaled by symptoms like hives, swelling of the face, or difficulty breathing.

---

Q: Is it possible for Streptomycin to interact with pain relievers like ibuprofen?

Regulatory guidance suggests that certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may interact with Streptomycin. Using high doses of these pain relievers concurrently may increase the risk of toxicity related to the medication.

---

Q: Is there a maximum time a person can safely be on Streptomycin?

Official caution regarding tuberculosis treatment advises that the total cumulative dose of Streptomycin should generally not exceed 120 grams over the entire course of treatment. Official guidance suggests the drug is discontinued if toxicity is observed.

---

Q: Why does Streptomycin sometimes cause a tingling sensation or numbness in the face or limbs?

Official side effect listings describe a sensation of paresthesia in the face or limbs. This tingling or numbness is a recognized symptom related to the neurotoxic effects of the drug. This symptom is a known sign of neurotoxicity.

---

Q: Can Streptomycin cause serious diarrhea, and how is that related to antibiotics in general?

Yes, official safety information lists persistent diarrhea that does not go away as a possible side effect. Diarrhea that does not go away can be a sign of a secondary infection, according to health guidance.

---

Q: What happens to Streptomycin in the body after it is administered?

After administration by deep injection, the drug is fully absorbed into the bloodstream, typically within four hours. The majority of the compound is then cleared from the body unchanged in the urine through the kidneys. This process of elimination is why kidney function is a crucial factor in monitoring treatment.

---

Q: What is the role of Streptomycin in treating plague or tularemia?

According to the official regulatory indications, Streptomycin is approved for the treatment of severe bacterial diseases, including both plague (Yersinia pestis) and tularemia (Francisella tularensis). Its use for these diseases is well-documented in authoritative medical sources.

---

Q: Why do some people experience injection site pain with Streptomycin?

Official safety information notes that local side effects are common with this injectable medication, which is given by deep intramuscular injection. These include experiencing pain, irritation, or redness at the site where the injection was given.

---

Q: Is it true that Streptomycin contains sulfites, and why is that important?

Official caution notes that the drug may contain sulfites. This means regulatory information states the drug is contraindicated in this population due to the risk of an allergic reaction.

---

Q: Does taking Streptomycin affect the effectiveness of birth control?

Official interaction summaries suggest that Streptomycin may interfere with the effectiveness of some hormonal therapies, such as specific types of estrogen. This interaction may occur by altering the bacterial balance in the gut, which can impact how the hormonal medication is processed.

---

Q: Can Streptomycin cause temporary or permanent changes to vision?

Yes, official side effect listings note that Streptomycin has the potential to cause adverse reactions related to sight. These include impaired vision, blurred vision, and potential optic nerve dysfunction.

---

Q: Does Streptomycin use carry a risk of secondary infection?

Regulatory warnings regarding antibiotics note a general risk of developing a new infection while taking the medication. This risk includes the potential for a serious secondary infection, such as Clostridium difficile, which is associated with antibiotic use.

How to Store and Dispose of Streptomycin?

The storage and disposal of Streptomycin sulfate (powder for solution for injection) must adhere strictly to regulatory requirements to maintain product stability and safety.

Storage Conditions

Condition	Requirement (Unreconstituted Powder)
Temperature	Do not store above 30°C.
Protection	Keep protected from light and humidity.

Stability and Handling

After the powder is mixed (reconstituted) with a sterile liquid, the solution's stability is limited to 24 hours when refrigerated at 2°C to 8°C. The medication must be kept in its original vial and stored out of the sight and reach of children.

Disposal Rules

Official guidelines state that unused or expired Streptomycin must not be discarded in wastewater or household trash. Disposal should follow established local and national regulations for pharmaceutical waste.